3-Oxo-2-piperazinyl acetamides as potent bradykinin B1 receptor antagonists for the treatment of pain and inflammation
摘要:
The discovery of novel and highly potent oxopiperazine based B1 receptor antagonists is described. Compared to the previously described arylsulfonylated (R)-3-amino-3-phenylpropionic acid series, the current compounds showed improved in vitro potency and metabolic stability. Compound 17, 2-((2R)-1-((4-methylphenyl)sulfonyl)-3-oxo-2-piperazinyl)-N-((1R)-6-(1-piperidinylmethyl)-1,2,3,4-tetrahydro-1-naphthalenyl) acetamide, showed EC(50) of 10.3 nM in a rabbit biochemical challenge model. The practical syntheses of chiral arylsulfonylated oxopiperazine acetic acids are also described. (C) 2011 Elsevier Ltd. All rights reserved.
Substituted sulfonamide compounds corresponding to formula I
pharmaceutical compositions comprising them, a process for preparing them, and the use of such compounds to treat or inhibit pain and other disorders or disease states.
Substituted sulfonamide compounds corresponding to formula I
pharmaceutical compositions comprising them, a process for preparing them, and the use of such compounds to treat or inhibit pain and other disorders or disease states.
[DE] SUBSTITUIERTE SULFONAMID-DERIVATE<br/>[EN] SUBSTITUTED SULFONAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE SULFONAMIDE SUBSTITUÉS
申请人:GRUENENTHAL GMBH
公开号:WO2008131947A1
公开(公告)日:2008-11-06
[EN] The present invention relates to substituted sulfonamide derivatives, methods for the production thereof, pharmaceuticals comprising said compounds, and the use of substituted sulfonamide derivatives for the production of pharmaceuticals. [FR] La présente invention concerne des dérivés de sulfonamide substitués, un procédé pour les préparer, des produits pharmaceutiques contenant ces composés et l'utilisation de dérivés de sulfonamide substitués pour préparer des produits pharmaceutiques. [DE] Die vorliegende Erfindung betrifft substituierte Sulfonamid-Derivate, Verfahren zu deren Herstellung, Arzneimittel enthaltend diese Verbindungen und die Verwendung von substituierten Sulfonamid-Derivaten zur Herstellung von Arzneimitteln.